Swapping IV for a pill? early test of oral arsenic for blood cancer
NCT ID NCT06882031
Summary
This early-stage study tested a new oral liquid form of the drug arsenic trioxide in 12 patients with a specific type of leukemia (APL). The main goal was to see how the body absorbs the oral drug compared to the standard IV version, and whether taking it with food or calcium changes its absorption. This research aims to see if a convenient pill could one day replace lengthy IV treatments for this cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA (APL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Hong Kong-Clinical Trial Centre Phase 1 Centre
Hong Kong, Hong Kong
Conditions
Explore the condition pages connected to this study.